General Atlantic, L.P.
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 13, 2025), General Atlantic, L.P. reported 16 stock positions worth $3.3 billion. Its top holding was Dlocal (DLO) at 20.0% of the portfolio, followed by XP Class A (XP, 14.4%) and Alignment Healthcare (ALHC, 12.7%). Compared with Q2 2025, it opened 1 new position, added to 3 and reduced 3. The biggest buy was a new position in Revolution Medicines (RVMD) and the biggest sale Alignment Healthcare (ALHC, shares −45%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001017645
- Portfolio Value
- $3.3B (Q3 2025)
- SEC Filing
- 0000950142-25-002960 ↗ filed Nov 13, 2025
Holdings Value
Holdings 16 stocks · $3.3B
| DLO Dlocal Ltd. | 20.00% | 46,656,695 | $666.3M | Reduce -27.0% |
| XP XP Inc. Class A | 14.39% | 25,517,733 | $479.5M | No change |
| ALHC Alignment Healthcare Inc. | 12.72% | 24,287,227 | $423.8M | Reduce -44.8% |
| CHYM Chime Financial Inc. Class A | 11.63% | 19,208,760 | $387.4M | No change |
| ALKT Alkami Technology Inc. | 8.94% | 11,991,480 | $297.9M | Add +24.3% |
| AKRO Akero Therapeutics Inc. | 8.17% | 5,733,989 | $272.2M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 7.05% | 9,681,818 | $234.8M | No change |
| PHVS Pharvaris NV | 6.02% | 8,031,252 | $200.4M | Add +6.6% |
| RVMD Revolution Medicines Inc. | 3.47% | 2,474,428 | $115.6M | New |
| BULL Webull Corp. | 3.20% | 7,198,867 | $106.5M | Add +0.7% |
| RPRX Royalty Pharma PLC Class A | 1.59% | 1,500,000 | $52.9M | No change |
| EWCZ European Wax Center Inc. Class A | 1.57% | 13,110,492 | $52.3M | No change |
| RSKD Riskified Ltd. Class A | 0.75% | 5,324,998 | $24.9M | No change |
| ADAG Adagene Inc.-ADR | 0.23% | 3,782,339 | $7.5M | Reduce -1.1% |
| ALMS Alumis Inc. | 0.16% | 1,297,530 | $5.2M | No change |
| GROV Grove Collaborative Holdings | 0.11% | 2,474,859 | $3.7M | No change |
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $2.9B | LFTO, DLO, CHYM, ALKT, XP |
| Q1 2026 | 12 | $2.1B | DLO, CHYM, XP, ALKT, PHVS |
| Q4 2025 | 13 | $2.9B | DLO, CHYM, XP, ALKT, ALHC |
| Q3 2025 | 16 | $3.3B | DLO, XP, ALHC, CHYM, ALKT |
| Q2 2025 | 15 | $3.6B | DLO, CHYM, ALHC, XP, AKRO |
| Q1 2025 | 15 | $3.0B | ALHC, DLO, XP, ALKT, AKRO |
| Q4 2024 | 16 | $2.8B | DLO, ALHC, ALKT, XP, CNTA |
| Q3 2024 | 18 | $3.5B | ALHC, XP, DLO, SQSP, ALKT |
| Q2 2024 | 19 | $3.2B | XP, DLO, ALKT, ALHC, SQSP |
| Q1 2024 | 22 | $4.3B | DLO, XP, ALKT, HRT, SQSP |